Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, raised $106 million by offering 5.9 million shares at $18, above the range of $14 to $16. Agios had originally planned to sell 5.0 million shares. Agios Pharmaceuticals plans to list on the NASDAQ under the symbol AGIO. J.P. Morgan and Goldman Sachs acted as joint bookrunners on the deal.
